Has the U.K. Biotech Industry valuation changed over the past few years?

Investors are relatively neutral on the British Biotechs industry at the moment, indicating that they anticipate long term growth rates to remain steady. The industry is trading close to its 3-year average PS ratio of 3.7x.

Which industries have driven the changes within the U.K. Healthcare industry?

There are no additional sub-industries under this industry.

U.K. (FTSE) Biotech Industry Analysis

Date	Market Cap	Revenue	Earnings	PE	Absolute PE	PS
Fri, 31 Jul 2026	UK£3.2b	UK£895.1m	-UK£152,242,548.80	18.2x	-21x	3.6x
Sun, 28 Jun 2026	UK£3.3b	UK£893.9m	-UK£154,372,096.20	18.5x	-21.6x	3.7x
Tue, 26 May 2026	UK£3.5b	UK£892.4m	-UK£149,274,968.20	19.3x	-23.7x	4x
Thu, 23 Apr 2026	UK£3.2b	UK£889.7m	UK£11.5m	12.3x	281.6x	3.6x
Sat, 21 Mar 2026	UK£3.1b	UK£875.5m	-UK£4,263,131.48	8.7x	-734.3x	3.6x
Mon, 16 Feb 2026	UK£3.8b	UK£876.0m	-UK£28,403,519.26	10.1x	-132.4x	4.3x
Wed, 14 Jan 2026	UK£3.4b	UK£876.1m	-UK£28,367,081.06	10.5x	-118.4x	3.8x
Fri, 12 Dec 2025	UK£3.2b	UK£896.8m	-UK£29,381,528.75	9.9x	-109.9x	3.6x
Sun, 09 Nov 2025	UK£3.1b	UK£886.5m	-UK£43,072,853.50	11.2x	-72.1x	3.5x
Tue, 07 Oct 2025	UK£3.3b	UK£878.6m	-UK£41,072,225.25	16.3x	-79.4x	3.7x
Thu, 04 Sep 2025	UK£3.3b	UK£855.8m	-UK£107,315,922.34	11.9x	-31.1x	3.9x
Sat, 02 Aug 2025	UK£3.1b	UK£855.0m	-UK£102,705,682.96	13x	-30.3x	3.6x
Mon, 30 Jun 2025	UK£2.6b	UK£854.5m	-UK£104,252,166.04	13x	-24.5x	3x
Wed, 28 May 2025	UK£2.5b	UK£879.1m	-UK£92,087,758.49	14x	-26.8x	2.8x
Fri, 25 Apr 2025	UK£2.1b	UK£876.4m	-UK£170,916,731.68	16.6x	-12.3x	2.4x
Sun, 23 Mar 2025	UK£2.4b	UK£844.1m	-UK£277,402,456.72	17.1x	-8.6x	2.8x
Tue, 18 Feb 2025	UK£2.7b	UK£841.7m	-UK£294,230,365.53	85.4x	-9.1x	3.2x
Thu, 16 Jan 2025	UK£2.7b	UK£842.6m	-UK£297,004,082.84	82.8x	-9x	3.2x
Sat, 14 Dec 2024	UK£2.6b	UK£841.7m	-UK£294,196,877.14	79.2x	-9x	3.1x
Mon, 11 Nov 2024	UK£2.8b	UK£840.3m	-UK£292,669,951.14	89.3x	-9.4x	3.3x
Wed, 09 Oct 2024	UK£2.9b	UK£840.1m	-UK£295,438,025.45	97.6x	-9.9x	3.5x
Fri, 06 Sep 2024	UK£2.8b	UK£834.8m	-UK£288,706,034.74	29.7x	-9.7x	3.3x
Sun, 04 Aug 2024	UK£2.6b	UK£838.1m	-UK£257,615,276.08	30.6x	-10.1x	3.1x
Tue, 02 Jul 2024	UK£2.5b	UK£835.9m	-UK£261,386,996.87	29.4x	-9.5x	3x
Thu, 30 May 2024	UK£2.9b	UK£836.3m	-UK£287,434,100.40	30.2x	-10.1x	3.5x
Sat, 27 Apr 2024	UK£3.1b	UK£895.9m	-UK£215,717,681.40	29.7x	-14.4x	3.5x
Mon, 25 Mar 2024	UK£3.1b	UK£900.2m	-UK£203,996,663.16	34.5x	-15.4x	3.5x
Wed, 21 Feb 2024	UK£3.2b	UK£913.4m	-UK£197,986,655.05	31.2x	-15.9x	3.5x
Fri, 19 Jan 2024	UK£6.3b	UK£1.3b	-UK£245,312,216.00	37.3x	-25.9x	5x
Sun, 17 Dec 2023	UK£6.1b	UK£1.3b	-UK£245,410,787.00	37x	-25x	4.8x
Tue, 14 Nov 2023	UK£6.3b	UK£1.3b	-UK£243,104,546.00	36.3x	-25.8x	4.9x
Thu, 12 Oct 2023	UK£6.6b	UK£1.3b	-UK£250,584,941.00	38.7x	-26.5x	5.2x
Sat, 09 Sep 2023	UK£6.5b	UK£1.3b	-UK£206,927,593.00	23.6x	-31.6x	5.1x
Mon, 07 Aug 2023	UK£6.9b	UK£1.3b	-UK£209,148,186.00	23.6x	-32.8x	5.4x


GB Market	2.36%
Healthcare	1.11%
Biotech	0.31%
Biotech	0.31%

Company	Last Price	7D	1Y	Valuation
GNS Genus	UK£22.44	4.1% +UK£58.9m	-10.1%	PE31.6x
SCLP Scancell Holdings	UK£0.098	-6.7% UK£9.8m	-4.4%	PS25.2x
FARN Faron Pharmaceuticals Oy	UK£0.42	2.4% +UK£2.2m	-78.2%	PE-4x
PBX ProBiotix Health	UK£0.08	6.7% +UK£790.8k	-20.0%	PS4.6x
BVXP Bioventix	UK£15.10	0.7% +UK£522.5k	-43.0%	PE10.6x

Announcement • Jul 27

Faron Pharmaceuticals Oy Announces Encouraging First Overall Survival Data from Frontline Higher-Risk Mds Patients in the Bexmab Phase 1/2 Trial

Faron Pharmaceuticals Oy has conducted its first overall survival (OS) data cut from treatment-naïve higher-risk myelodysplastic syndrome (HR-MDS) patients enrolled in the BEXMAB trial. After a median follow-up of 14.9 months, median overall survival has not yet been reached in frontline HR MDS without TP53 mutations, nor has it yet been reached for monoallelic TP53 mutated patients. For patients with biallelic TP53 mutations the median OS is 8.8 months in line with historical results in this highly aggressive population. At this time, after a median follow-up of 14.9 months, the only subgroup to have hit the median is the biallelic TP53 mutated population. This subgroup, historically associated with very poor outcomes, achieved a median OS of 8.8 months, which is in line with historical data and reassuring given the complex cytogenetics within the BEXMAB biallelic patient population. Other subgroups: monoallelic TP53 mutated and wildtype patients have still not reached their median OS. The BEXMAB trial is an open-label Phase 1/2 study investigating bexmarilimab, Faron's novel anti-Clever-1 immunotherapy, in combination with standard-of-care azacitidine in patients with higher-risk myelodysplastic syndromes. Of the 21 treatment-naïve HR-MDS patients, 48% harboured TP53 mutations, a well-established adverse prognostic factor associated with inferior survival outcomes. Of the TP53 mutated patients (with known allele frequency data), 33% had monoallelic TP53 alterations, and 67% had biallelic TP53 alterations. Survival follow-up is ongoing, and several patients remain alive and under follow-up, providing the opportunity for further maturation of the dataset over time. Bexmarilimab is Faron’s wholly owned, investigational immunotherapy designed to overcome resistance to existing treatments and optimize clinical outcomes, by targeting myeloid cell function and igniting the immune system. Bexmarilimab binds to Clever-1, an immunosuppressive receptor found on macrophages leading to tumor growth and metastases (i.e. helps cancer evade the immune system). By targeting the Clever-1 receptor on macrophages, bexmarilimab alters the tumor microenvironment, reprogramming macrophages from an immunosuppressive (M2) state to an immunostimulatory (M1) one, upregulating interferon production and priming the immune system to attack tumors and sensitizing cancer cells to standard of care.

Announcement • Jun 22

Solvonis Therapeutics Announces Positive Bridging Data Supporting Planned U.S. 505(b)(2) Pathway Towards Phase 2b Clinical Trial of SVN-002

Solvonis Therapeutics plc announced positive pharmacokinetic (PK) data from the preclinical bridging study for its SVN-002 development programme. SVN-002 is Solvonis' proprietary esketamine oral thin-film (OTF) formulation being developed for moderate-to-severe Alcohol Use Disorder (AUD) in the United States. It is designed for supervised, clinic-administered sublingual-buccal dosing. The programme also incorporates a structured alcohol education component, intended for future remote digital access by patients. The programme is being advanced under a planned U.S. Food and Drug Administration (FDA) 505(b)(2) regulatory pathway referencing the FDA-approved intranasal esketamine product, Spravato®. The nonclinical study was designed to assess whether the intended combined sublingual-buccal administration of SVN-002 could generate systemic esketamine exposure supportive of a scientific bridge to the approved intranasal esketamine reference product. At the same nominal dose level, combined sublingual-buccal administration of SVN-002 produced rapid systemic exposure to parent esketamine. Exposure levels for parent esketamine and the key measured metabolites, noresketamine and hydroxynoresketamine, were within the range observed for the intranasal esketamine comparator arm, providing important translational support for the planned scientific bridge. At the December 2024 Type B pre-IND meeting held with the FDA by Awakn Life Sciences, prior to the asset's acquisition by Solvonis, FDA identified systemic exposure to esketamine and relevant metabolite exposure as key considerations for the initial Investigational New Drug (IND) package. Solvonis believes these newly generated data provide important translational support in relation to the FDA-identified exposure considerations and strengthen the planned initial IND package for SVN-002. Following these positive results, Solvonis will seek further FDA feedback on the scope and scale of the remaining nonclinical toxicology work required for the initial IND submission. Subject to FDA feedback and successful completion of this targeted toxicology package, Solvonis plans to submit an IND to support the initiation of a Phase 2b clinical trial of SVN-002 in patients with moderate-to-severe AUD in the United States. AUD represents a major and underserved U.S. market opportunity characterised by limited pharmacological innovation. According to the 2024 U.S. National Survey on Drug Use and Health, approximately 27,900,000 people aged 12 and older in the U.S. had Alcohol Use Disorder in the past year. Solvonis estimates that approximately 15,000,000 U.S. adults fall within the programme's target moderate-to-severe AUD population. Spravato® provides a relevant commercial reference point for supervised, clinic-administered esketamine treatment models. Johnson & Johnson reported worldwide Spravato® sales of approximately USD 1,700 million in 2025 for depression-related indications. Solvonis estimates that SVN-002's target U.S. moderate-to-severe AUD population is approximately five times larger than the estimated U.S. treatment-resistant depression comparator population of approximately 2,800,000 people. The planned 505(b)(2) pathway is central to the capital efficiency of the SVN-002 development strategy. A successful 505(b)(2) route may allow Solvonis to rely, in part, on the FDA's prior findings of safety and/or effectiveness for the approved intranasal esketamine reference product, provided a suitable scientific bridge is established. Solvonis intends to build the SVN-002 package using existing third-party preclinical data, in-licensed Phase 1 clinical data, and targeted SVN-002 bridging and toxicology studies, rather than duplicating a full conventional de novo development package. The Company believes this approach has the potential to reduce development expenditure and support a more capital-efficient route towards Phase 2b. The pharmacokinetic profile observed in this study is very encouraging. Combined sublingual-buccal administration produced rapid systemic exposure to parent esketamine and supports the core rationale for SVN-002 as a transmucosal thin-film product. These results provide important translational evidence for the planned U.S. regulatory pathway and support SVN-002's continued development as a supervised, clinic-administered treatment candidate for AUD.

U.K. (FTSE) Biotech Industry Analysis

Industry Valuation and Performance

Industry Trends

Top Stock Gainers and Losers

Latest News

New minor risk - Shareholder dilution

Faron Pharmaceuticals Oy Announces Encouraging First Overall Survival Data from Frontline Higher-Risk Mds Patients in the Bexmab Phase 1/2 Trial

Consensus EPS estimates fall by 27%

An asymmetric deep-value biotech incubator trapped in a severe conglomerate discount despite recurring proof of multi-billion dollar asset.

Aptamer Group PLC Provides Earnings Guidance for the Fiscal Year 2026

Avacta Group plc Announces Appointment of Patrick Vink as Non-Executive Deputy Chairman and Senior Independent Director

GNS: Gene Editing Progress Will Drive Medium-Term Upside Potential

SkinBioTherapeutics plc Announces Termination of Emily Lorraine Bertram as Director, Effective June 30, 2026

Palatin Technologies, Inc., Annual General Meeting, Jul 28, 2026

Solvonis Therapeutics Announces Positive Bridging Data Supporting Planned U.S. 505(b)(2) Pathway Towards Phase 2b Clinical Trial of SVN-002

Investor sentiment improves as stock rises 18%

Hemogenyx Pharmaceuticals Plc, Annual General Meeting, Jun 30, 2026

Genflow Biosciences plc, Annual General Meeting, Jun 29, 2026

ProBiotix Health Plc, Annual General Meeting, Jun 23, 2026

OptiBiotix Health Plc, Annual General Meeting, Jun 23, 2026